Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | CPT1A | P50416 | 6/20 | 0.32 |
| ▸ | CPT2 | P23786 | 3/20 | 0.31 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.31 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.31 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581033 | 0.91 | TP53 (0.36) | CPT1ACPT2CPT1BTRPC3TRPC7 | |
| SCHEMBL3579063 | 0.87 | GRIN2B (0.34) | GRIN1GRIN2BSMN1; SMN2TLR9TLR8 | |
| SCHEMBL3592264 | 0.87 | CPT1A (0.33) | GRIN1GRIN2BCPT1ACPT2CPT1B | |
| SCHEMBL3582566 | 0.87 | GRIN2B (0.33) | RORCGRIN1GRIN2BCPT1ACPT2 | |
| SCHEMBL3589486 | 0.86 | GRIN2B (0.43) | GRIN1GRIN2B | |
| SCHEMBL3590376 | 0.86 | TRPC3 (0.41) | CPT1ACPT2TRPC3TRPC7LMNA | |
| SCHEMBL3576053 | 0.85 | PIN1 (0.43) | NPC1RAB9ASMN1; SMN2CPT1ACPT2 | |
| SCHEMBL3588606 | 0.85 | CPT1A (0.44) | CPT1ACPT2CPT1B | |
| SCHEMBL3581616 | 0.84 | MAPK1 (0.41) | SMN1; SMN2LMNA | |
| SCHEMBL3591786 | 0.84 | CPT1A (0.37) | NPC1RAB9ASMN1; SMN2CPT1ACPT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | claimed |
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286191-A1 | 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CXCR2 | RORC 85/4885GRIN1 571/4885GRIN2B 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.